Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28449489 | 0.73 | KDM4E (0.33) | — | |
| SCHEMBL29202325 | 0.71 | KDM4E (0.31) | — | |
| SCHEMBL4982209 | 0.71 | KDM4E (0.31) | LMNA | |
| SCHEMBL7701050 | 0.71 | CA1 (0.35) | CA1LMNAALOX15BLMPMP22 | |
| SCHEMBL4573542 | 0.69 | CA1 (0.31) | CA1 | |
| SCHEMBL7642164 | 0.69 | ALOX5 (0.32) | LMNA | |
| Acetamide SCHEMBL28743112 | 0.69 | LMNA (0.50) | CA1LMNAALOX15BLMPMP22 | |
| SCHEMBL28161482 | 0.69 | CA2 (0.35) | CA1LMNAALOX15BLMPMP22 | |
| Dimethyl Sulfone SCHEMBL7897755 | 0.68 | — | — | |
| SCHEMBL7581203 | 0.67 | F2 (0.36) | F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002070507-A2 | GLYCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF DIABETES | ABBOTT LABORATORIES (US) | 2002-09-12 | — | — | WO | claimed |
| US-12486276-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | PYRAMID BIOSCIENCES, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240246976-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES INC (US) | 2024-07-25 | — | — | US | disclosed |
| US-11773127-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| CN-111819179-B | Related compounds as TRK kinase inhibitors for the treatment of cancer | 金字塔生物科技公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 2021-06-10 | — | — | US | disclosed |
| CN-107001337-B | Pyrrolidine derivatives as angiotensin II type antagonists | 诺华股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-3245198-B1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | NOVARTIS AG (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-12-28 | — | — | US | disclosed |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-6569856-B2 | Treatment of feeding disorders, obesity, bulimia nervosa, sexual/reproductive disorders, depression, epileptic seizure, cardiovascular disorders, sleep disturbances | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-05-27 | — | — | US | disclosed |
| EP-1183245-A4 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-01 | — | — | US | disclosed |
| EP-1183245-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6340683-B1 | NEUROPEPTIDE Y ANTAGONISTS; TREATING EATING DISORDERS, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION, EPILEPTIC SEIZURE, HYPERTENSION, CEREBRAL HEMORRHAGE, CONGESTIVE HEART FAILURE, SLEEP DISTURBANCES | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-22 | — | — | US | disclosed |
| WO-2000064880-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
| EP-1027350-A1 | AMINOMETHYL-BENZO A]QUINOLIZIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATIONS FOR NEURODEGENRATIVE DISEASES | PIERRE FABRE MEDICAMENT (FR) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021856-A1 | AMINOMETHYL-BENZO[A]QUINOLIZIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATIONS FOR NEURODEGENRATIVE DISEASES | PIERRE FABRE MEDICAMENT (FR) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | CA1 3118/4885LMNA 4620/4885ALOX15 760/4885 |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | AGTR2, AGTR1, AVPR2 | CA1 2977/4885LMNA 4695/4885ALOX15 1688/4885 |
| US-12486276-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | DTYMK, DCK, MAP3K9 | CA1 4880/4885LMNA 3519/4885ALOX15 3824/4885 |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | AGTR2, AGTR1, ACE2 | CA1 3512/4885LMNA 4630/4885ALOX15 1483/4885 |
| US-20240246976-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | DTYMK, DCK, MAP3K9 | CA1 4880/4885LMNA 3519/4885ALOX15 3824/4885 |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | CA1 3118/4885LMNA 4620/4885ALOX15 760/4885 |
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, MPO | CA1 1677/4885LMNA 3131/4885ALOX15 331/4885 |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | CA1 3471/4885LMNA 4406/4885ALOX15 921/4885 |
| US-11773127-B2 | Compounds and methods for treating bacterial infections | MMP8, ELANE, MPO | CA1 1677/4885LMNA 3131/4885ALOX15 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.